|
|
| |
| |
 |
 |
HIV and Immunodeficiency Viruses
ImQuest has decades of experience with the efficient and cost-effective development of anti-HIV therapeutics. Laboratory generated data and technical project reports have been subjected to rigorous evaluation by the FDA, and have lead to the successful entrance of therapeutic agents into human clinical trials.
 |
HIV-1, HIV-2, SIV |
|
Chemokine receptor specific panels |
|
Clinical subtype viruses |
|
Monocyte-tropic viruses |
|
Drug resistant virus panels |
|
Multi-drug resistant viruses |
|
 |
Hepatitis Viruses
Using state of the art and established in vitro models, ImQuest rapidly identifies therapeutic agents with the potential to inhibit the replication of Hepatitis B and Hepatitis C. Cell-based and biochemical assays are designed to define the precise mode of action of the test agent and to compare the activity of novel molecules to existing approved therapeutics. Combination and resistance testing is performed to confirm the clinical potential of the agent.
|
Hepatitis B & Hepatitis C viruses |
|
Replicon models |
|
BVDV |
|
Other flaviviruses |
|
|
Respiratory & Enteric Viruses
ImQuest is developing new models and assays that will expedite research in anti-respiratory viruses. Focal areas are the development of programs and assays for anti-influenza and anti-RSV research. In order to remain technologically current in the anti-respiratory virus field, ImQuest staff constantly search for new wild type and drug resistant viral strains and evaluate the activity of existing approved and experimental compounds for activity against these strains alone and in combination.
|
Influenza A/B, respiratory syncytial virus |
|
Adenovirus, coxsackie A/B |
|
Parainfluenza, measles, rhinovirus |
|
Enterovirus, echovirus, poliovirus |
|
|
Herpes Viruses
ImQuest currently offers primary screening assays to identify inhibitors of human herpesviruses. In addition, ImQuest has the ability to perform a wide variety of secondary assays to determine compound range and mechanism of action, as well as activity in combination with approved drugs.
|
HSV-1, HSV-2, HCMV, VZV |
|
EBV, HHV-6, HHV-8 |
|
|
Microbial Pathogens
ImQuest maintains panels of bacteria and fungi that cause specific disease indications, such as organisms that cause sexually transmitted diseases, respiratory infections, digestive system diseases, and skin and topical diseases. ImQuest has focused on anti-microbial therapies for topical microbicides and hospital acquired pathogens, including drug resistant organisms, such as MRSA and VRE. Appropriate animal models, including the neutropenic thigh infection model, are used to confirm in vivo efficacy of selected drug candidates.
|
STI pathogens |
|
Topical, respiratory & digestive pathogens |
|
|
Topical Microbicides Development
ImQuest’s topical microbicide program provides laboratory and consulting support to the scientific community dedicated to developing safe, cost-effective and efficacious anti-infective topical microbicides. The depth and breadth of these microbicide services are entirely unique and offer the ability to rapidly define microbicide candidates with clinical potential. Collaborating with experts in animal modeling, formulations, safety assessment and clinical trials, ImQuest provides the necessary technology to efficiently transition to clinical microbicide development.
|
In vitro range and mechanism of action |
|
Evaluation versus other STIs |
|
Modeling of activity in vaginal environment |
|
Transmission assays |
|
Combination microbicide therapy |
|
Gel and other formulations |
| |
|
|
Cervical explant and tissue modeling |
|
|
|
| |
| |
| Copyright © 2010, ImQuest BioSciences. | | | |
| | | | | |
| | | | |
| |
|
|
|
